Skip to main content
. 2021 Sep 13;39(9):1262–1278.e7. doi: 10.1016/j.ccell.2021.07.003

Figure 5.

Figure 5

EWF/FLI is a neomorphic substrate of TRIM8 for degradation

(A) 293T cells were transfected with the indicated constructs for 48 h and then treated with 500 nM carfilzomib for 6 h, lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. Data representative of three independent experiments.

(B) 293T cells were transfected with the indicated constructs for 48 h and treated with DMSO or 500 nM carfilzomib for 6 h. Cells were then lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. Data representative of three independent experiments.

(C) 293T cells transfected with either fusion oncoproteins or WT counterparts for 48 h were treated with 1 μM carfilzomib for 6 h, lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. Data representative of three independent experiments.

(D) 293T cells were transfected with the indicated constructs for 48 h then lysed, immunoprecipitated, and immunoblotted with the indicated antibodies. Data representative of three independent experiments.

(E) 293T cells were transfected with either FLAG-tagged fusion oncoproteins or WT counterparts for 48 h, lysed, and immunoblotted with the indicated antibodies. Data representative of three independent experiments.